Abstract
Background: Non-suicidal self-injury (NSSI) is a deliberate, repetitive act resulting in tissue damage without suicidal intent and is frequently associated with depressive disorders. Nesfatin-1, an anorexigenic peptide expressed in the hypothalamus, has been implicated in stress-related psychopathologies beyond its metabolic functions. This study aimed to investigate the relationship between serum nesfatin-1 levels and non-suicidal self-injury in adolescents diagnosed with major depressive disorder (MDD). Methods: This study included 40 adolescents aged 12–18 years with MDD, 41 adolescents with MDD and comorbid NSSI, and 45 healthy controls. All participants were medication-free for at least eight weeks prior to enrollment. Psychiatric diagnoses were established using K-SADS-PL. Depressive symptom severity and self-injurious behaviors were assessed using the CDI and ISAS, respectively. Serum nesfatin-1 levels were measured using a sandwich enzyme-linked immunosorbent assay (ELISA). Results: Serum nesfatin-1 levels differed significantly among the three groups ( p < 0.001) and were highest in the MDD+NSSI group. Both patient groups exhibited significantly higher nesfatin-1 levels than healthy controls, and the MDD+NSSI group showed significantly higher levels than the MDD group ( p = 0.010), despite comparable depressive symptom severity between the two patient groups. Serum nesfatin-1 levels were positively correlated with depressive symptom severity (Spearman’s ρ = 0.691, p < 0.001). ROC curve analyses demonstrated good discriminative ability of nesfatin-1 for distinguishing patient groups from healthy controls and fair discriminative ability for differentiating adolescents with MDD+NSSI from those with MDD alone (AUC = 0.671, 95% CI: 0.553–0.789, p = 0.008). CDI scores did not differ between the two patient groups ( p = 0.059) despite both being significantly higher than those of the control group ( p < 0.001). Conclusions: Serum nesfatin-1 levels were associated with both depressive symptom severity and NSSI in adolescents with MDD. Notably, nesfatin-1 levels differentiated adolescents with MDD+NSSI from those with MDD alone despite comparable depressive symptom severity between the two patient groups. These findings suggest that nesfatin-1 may be involved in neurobiological processes underlying self-injurious behavior in adolescent depression. Future longitudinal studies with larger samples are needed to further clarify the role and clinical relevance of nesfatin-1 in adolescents with depression and NSSI. Trial registration: Not applicable.
Funding Information
  • Giresun University Scientific Research Projects Coordination Unit (SAĞ-BAP-A-290224-52)

This publication has 31 references indexed in Scilit: